Crossmark

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Published Online: 2023-09-29

Published Print: 2023-12

Authors

Dunleavy, Katie A.

Raffals, Laura E. https://orcid.org/0000-0002-5267-2592
Camilleri, Michael
Funding

Funding for this research was provided by:

National Institute for Health Care Management Foundation (R01-DK115950)
License Information

Text and Data Mining valid from 2023-09-29

Version of Record valid from 2023-09-29
More Information

Article History

Received: 14 February 2023

Accepted: 19 September 2023

First Online: 29 September 2023

Declarations

:

: KAD has no conflicts of interest. LER is on the Advisory Board for Fresenius Kabi Gastroenterology and Janssen Pharmaceuticals. MC has stock options for consulting with Thelium Therapeutics (epithelial barrier function) re: divertin.

Document is current